

Special Issue

The Effectiveness of Pneumococcal Conjugate Vaccines

Message from the Guest Editor

Pneumococcal disease is a vaccine-preventable illness that causes a significant amount of mortality worldwide, particularly among children aged under five years old. In those who have been vaccinated, there has been a decrease in infections caused by vaccine serotypes, and the lower carriage of these serotypes has led to herd protection benefits for those who have not been vaccinated; however, the positive effects of conjugate vaccines have been undermined by the emergence and spread of non-vaccine serotypes, which threaten the efficacy of currently available vaccines. Many studies have been conducted globally to examine the effectiveness of pneumococcal conjugate vaccines; however, ongoing research is still necessary to ensure the proper surveillance of pneumococcal disease until universal pneumococcal vaccines are developed. We invite contributions of original reports, observations, or reviews on the following topics:

- Pneumococcal disease and vaccines.
- Vaccination and epidemiology.
- Current vaccines and emerging serotypes.
- Baseline studies of the PCV13 serotype before the implementation of higher-valent conjugate vaccines.

Guest Editor

Dr. Jose María Marimón

1. Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Microbiology Department, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, 20014 San Sebastian, Spain
2. Servicio de Microbiología, Hospital Universitario Donostia, Paseo Dr Beguiristain s/n, 20014 Donostia-San Sebastián, Spain

Deadline for manuscript submissions

closed (31 May 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/192645

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).